18F-BMS-986229 / BMS 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Assessing PD-L1 without a biopsy and through PD-L1 PET imaging with 18F-BMS-986229. (Available On Demand; 233) -  Apr 28, 2022 - Abstract #ASCO2022ASCO_1638;    
    P2
    The signal of PD-L1 positivity by PET imaging with 18F-BMS-986229 at baseline appears associated with early efficacy from nivo + ipi in this small cohort and may offer additional information than PD-L1 IHC. The ability to assess PD-L1 on a whole patient level at multiple timepoints on treatment may have future implications in how best to sequence and combine immunotherapies but further study in larger patient cohorts is needed.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Trial completion date, Trial primary completion date:  A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer (clinicaltrials.gov) -  Nov 15, 2021   
    P=N/A,  N=35, Recruiting, 
    The ability to assess PD-L1 on a whole patient level at multiple timepoints on treatment may have future implications in how best to sequence and combine immunotherapies but further study in larger patient cohorts is needed. Trial completion date: Nov 2022 --> Nov 2023 | Trial primary completion date: Nov 2022 --> Nov 2023